{{Rsnum
|rsid=28399499
|Gene=CYP2B6
|Chromosome=19
|position=41012316
|Orientation=plus
|GMAF=0.0202
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=CYP2B6
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 0.0 | 0.0 | 0.0
| HCB | 0.0 | 0.0 | 0.0
| JPT | 0.0 | 0.0 | 0.0
| YRI | 2.7 | 19.0 | 78.2
| ASW | 1.8 | 14.0 | 84.2
| CHB | 0.0 | 0.0 | 0.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 13.8 | 86.2
| MEX | 0.0 | 1.7 | 98.3
| MKK | 0.6 | 2.6 | 96.8
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs28399499
|Name_s=c.983T>C
|Gene_s=CYP2A7P1, CYP2B6
|Feature=
|Evidence=PubMed ID:20017669
|Annotation=Risk or phenotype-associated allele: TC. Phenotype: This variant is statistically correlated with the mean of maximum transaminase values (ALT) in patients from Mozambique, with ALT mean value of 91.68 U/l for TT, and 221.45 U/l for TC genotypes (p < 0.001). Study size: 156. Study population/ethnicity: HIV infected patients from Mozambique. Significance metric(s): p< 0.001. Type of association: GN; CO
|Drugs=nevirapine
|Drug Classes=
|Diseases=Drug Toxicity; HIV Infections
|Curation Level=Curated
|PharmGKB Accession ID=PA165111622
}}

{{PharmGKB
|RSID=rs28399499
|Name_s=CYP2B6: 983T>C; I328T
|Gene_s=CYP2A7P1, CYP2B6
|Feature=
|Evidence=PubMed ID:16272958; PubMed ID:16495778; PubMed ID:17638512; Web Resource:http://www.cypalleles.ki.se/cyp2b6.htm
|Annotation=This variant in exon 7 defines the CYP2B6*18 allele and is part of the *16 allele. Recombinant expression of this variant resulted in an undetectable expression and activity in COS-1 cells but expression of a protein with reduced activity in insect cells. The I328T variant was found in HIV patients with strongly elevated plasma concentrations of efavirenz, especially in individuals of African descent.
|Drugs=efavirenz
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA162355701
}}

{{PharmGKB
|RSID=rs28399499
|Name_s=CYP2B6:983T>C; CYP2B6:Ile328Thr; part of CYP2B6*18
|Gene_s=CYP2A7P1, CYP2B6
|Feature=
|Evidence=Web Resource:http://www.pharmgkb.org/search/annotatedGene/cyp2b6/variant.jsp
|Annotation=This variant is the only protein coding change in the CYP2B6*18 allele. Its phenotype with respect to drugs is unclear. See VIP annotation for more details.
|Drugs=bupropion; efavirenz; nevirapine
|Drug Classes=
|Diseases=
|Curation Level=In-Depth
|PharmGKB Accession ID=PA164891494
}}

{{PMID Auto
|PMID=21886015
|Title=Cytochrome P450 CYP2B6 genotypes and haplotypes in a Colombian population: identification of novel variant CYP2B6 alleles
}}

{{PMID Auto
|PMID=18728241
|Title=Pharmacokinetics of efavirenz when co-administered with rifampin in TB/HIV co-infected patients: pharmacogenetic effect of CYP2B6 variation.
|OA=1
}}

{{PMID Auto
|PMID=19239339
|Title=Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or efavirenz in African americans.
|OA=1
}}

{{PMID Auto
|PMID=19371316
|Title=CYP2B6 (c.516G-->T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIV-infected patients.
|OA=1
}}

{{PMID Auto
|PMID=19659438
|Title=CYP2B6 variants and plasma efavirenz concentrations during antiretroviral therapy in Port-au-Prince, Haiti.
|OA=1
}}

{{PMID Auto
|PMID=23080225
|Title=Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants
|OA=1
}}

{{GET Evidence
|gene=CYP2B6
|aa_change=Ile328Thr
|aa_change_short=I328T
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs28399499
|overall_frequency_n=229
|overall_frequency_d=10758
|overall_frequency=0.0212865
|n_genomes=1
|n_genomes_annotated=0
|n_haplomes=1
|n_articles=1
|n_articles_annotated=1
|in_pharmgkb=Y
|pph2_score=1.0
|nblosum100=3
|autoscore=3
|webscore=N
|summary_short=Elevated plasma levels of efavirenz. Also associated with response to bupropion and nevirapine.
}}

{{PMID Auto
|PMID=22951632
|Title=Underlying genetic structure impacts the association between CYP2B6 polymorphisms and response to efavirenz and nevirapine
|OA=1
}}

{{PMID Auto
|PMID=24080498
|Title=Pharmacogenetic associations with plasma efavirenz concentrations and clinical correlates in a retrospective cohort of Ghanaian HIV-infected patients
}}

{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}